PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPerphenazine
Perphenazine
Perphenazine (perphenazine) is a small molecule pharmaceutical. Perphenazine was first approved as Triavil 2-25 on 1982-01-01. It is used to treat huntington disease, nausea, psychotic disorders, reye syndrome, and schizophrenia amongst others in the USA. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, histamine H1 receptor, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
chemically-induced disordersD064419
mental disordersD001523
Trade Name
FDA
EMA
Perphenazine (discontinued: Perphenazine, Trilafon)
Combinations
Perphenazine amitriptyline (discontinued: Etrafon, Perphenazine amitriptyline, Triavil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amitriptyline hydrochloride
+
Perphenazine
Tradename
Company
Number
Date
Products
TRIAVIL 2-25New River PharmaceuticalsN-014715 DISCN1982-01-01
1 products
TRIAVIL 4-10New River PharmaceuticalsN-014715 DISCN1982-01-01
1 products
TRIAVIL 2-10New River PharmaceuticalsN-014715 DISCN1982-01-01
1 products
TRIAVIL 4-25New River PharmaceuticalsN-014715 DISCN1982-01-01
1 products
TRIAVIL 4-50New River PharmaceuticalsN-014715 DISCN1982-01-01
1 products
ETRAFON-AMerck & CoN-014713 DISCN1982-01-01
1 products
ETRAFON 2-25Merck & CoN-014713 DISCN1982-01-01
1 products
ETRAFON-FORTEMerck & CoN-014713 DISCN1982-01-01
1 products
ETRAFON 2-10Merck & CoN-014713 DISCN1982-01-01
1 products
Hide discontinued
Perphenazine
Tradename
Company
Number
Date
Products
TRILAFONMerck & CoN-010775 DISCN1982-01-01
4 products, RLD
TRILAFONMerck & CoN-011213 DISCN1982-01-01
1 products
TRILAFONMerck & CoN-011294 DISCN1982-01-01
1 products
TRILAFONMerck & CoN-011361 DISCN1982-01-01
1 products
TRILAFONMerck & CoN-011557 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
perphenazineANDA2025-06-05
perphenazine and amitriptyline hydrochlorideANDA2025-03-15
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N05: Psycholeptics
N05A: Antipsychotics
N05AB: Phenothiazines with piperazine structure, antipsychotics
N05AB03: Perphenazine
HCPCS
Code
Description
J3310
Injection, perphenazine, up to 5 mg
Q0175
Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
Clinical
Clinical Trials
31 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20237618
Psychotic disordersD011618F20.8112328
Weight gainD015430112
Schizophrenia spectrum and other psychotic disordersD01996711
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704EFO_0003862F0322
Mental disordersD001523EFO_0000677F91.922
VomitingD014839R11.111
NauseaD009325R11.011
Psychophysiologic disordersD011602F45.911
DepressionD003863F33.911
Anxiety disordersD001008EFO_0006788F41.111
Somatoform disordersD013001F4511
Disease progressionD01845011
Vascular dementiaD015140F0111
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients313
StrokeD020521EFO_0000712I63.9112
Cocaine-related disordersD019970F14122
Mood disordersD019964EFO_0004247F30-F3911
Ischemic strokeD00008324211
IschemiaD007511EFO_000055611
Cerebral infarctionD002544I6311
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug interactionsD004347112
ObesityD009765EFO_0001073E66.911
Body weightD001835EFO_000433811
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bipolar disorderD001714EFO_0000289F30.922
Drug-related side effects and adverse reactionsD064420T88.711
RecurrenceD01200811
Type 2 diabetes mellitusD003924EFO_0001360E1111
EmergenciesD00463011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePerphenazine
INNperphenazine
Description
Perphenazine is a phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10. It has a role as a phenothiazine antipsychotic drug, a dopaminergic antagonist and an antiemetic. It is a member of phenothiazines, a N-alkylpiperazine, a N-(2-hydroxyethyl)piperazine and an organochlorine compound. It derives from a hydride of a 10H-phenothiazine.
Classification
Small molecule
Drug classTypical antipsychotic
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
Identifiers
PDB
CAS-ID58-39-9
RxCUI
ChEMBL IDCHEMBL567
ChEBI ID8028
PubChem CID4748
DrugBankDB00850
UNII IDFTA7XXY4EZ (ChemIDplus, GSRS)
Target
Agency Approved
DRD2
DRD2
Organism
Homo sapiens
Gene name
DRD2
Gene synonyms
NCBI Gene ID
Protein name
D(2) dopamine receptor
Protein synonyms
Dopamine D2 receptor, seven transmembrane helix receptor
Uniprot ID
Mouse ortholog
Drd2 (13489)
D(2) dopamine receptor (Q0VGH9)
Alternate
HTR2A
HTR2A
HTR2C
HTR2C
HRH1
HRH1
HTR7
HTR7
HTR6
HTR6
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Perphenazine
+
Amitriptyline
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Perphenazine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,603 documents
View more details
Safety
Black-box Warning
Black-box warning for: Perphenazine, Perphenazine and amitriptyline hydrochloride
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,672 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use